0001192482-21-000103.txt : 20210122
0001192482-21-000103.hdr.sgml : 20210122
20210122161351
ACCESSION NUMBER: 0001192482-21-000103
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210119
FILED AS OF DATE: 20210122
DATE AS OF CHANGE: 20210122
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ciaffoni Joseph
CENTRAL INDEX KEY: 0001443841
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37372
FILM NUMBER: 21545933
MAIL ADDRESS:
STREET 1: 100 TECHNOLOGY CENTER DRIVE
CITY: STOUGHTON
STATE: MA
ZIP: 02072
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC
CENTRAL INDEX KEY: 0001267565
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: VA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 TECHNOLOGY CENTER DRIVE
CITY: STOUGHTON
STATE: MA
ZIP: 02072
BUSINESS PHONE: 781-713-3699
MAIL ADDRESS:
STREET 1: 100 TECHNOLOGY CENTER DRIVE
CITY: STOUGHTON
STATE: MA
ZIP: 02072
FORMER COMPANY:
FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC
DATE OF NAME CHANGE: 20031020
4/A
1
edgar.xml
PRIMARY DOCUMENT
X0306
4/A
2021-01-19
2021-01-21
0001267565
COLLEGIUM PHARMACEUTICAL, INC
COLL
0001443841
Ciaffoni Joseph
C/O COLLEGIUM PHARMACEUTICAL, INC.
100 TECHNOLOGY CENTER DRIVE
STOUGHTON
MA
02072
1
1
0
0
President and CEO
Common Stock
2021-01-19
4
A
0
105000
0
A
289256
D
Common Stock
2021-01-19
4
A
0
28989
A
318245
D
Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2022, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.
On January 19, 2021, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to 28,989 performance share units granted in two prior years.
The original Form 4 filed on January 21, 2021 is amended by this Form 4 amendment to reflect the correct number of securities acquired by the reporting person. Due to an administrative error, the original Form 4 misreported a grant of stock options to the reporting person on January 19, 2021. No such grant was made. The transactions listed in Table I of this Form 4 amendment are not new or revised. The transactions listed in Table I of this Form 4 amendment are being reported again solely in order to gain access to the system for purposes of effecting this amendment.
/s/ Paul Brannelly as Attorney-In-Fact For Joseph Ciaffoni
2021-01-22